Sangre AgroTech, a wholly-owned subsidiary of WEED, Inc., is a plant genomic research and breeding company specializing in the development and application of cannabis-derived compounds for the treatment of human diseases. Established in 2017, Sangre AgroTech is headquartered in La Veta, Colorado. The company's mission is to advance cannabis research by creating a comprehensive genomic classification of the Cannabis plant genus, aiming to develop scientifically validated and evidence-based cannabis strains for disease-specific medicines.
Key Strategic Focus
Sangre AgroTech's primary strategic objective is to complete a five-year Cannabis Genomic Study to map the genetic blueprint of the Cannabis plant. This initiative involves sequencing various cannabis strains to identify and isolate genomic regions related to growth, synthesis of desired molecules, and resistance to environmental stressors. The company plans to utilize this data in a breeding program to generate new hybrid cultivars with traits beneficial for medical applications. The ultimate goal is to patent and archive a collection of highly active medicinal strains, thereby creating intellectual property that adds significant value to the company.
Financials and Funding
As of the latest available data, Sangre AgroTech has been acquired by WEED, Inc. The acquisition details include a share exchange agreement where WEED, Inc. acquired all issued and outstanding membership units of Sangre AgroTech in exchange for 500,000 shares of WEED, Inc.'s common stock. This strategic move was aimed at bolstering WEED, Inc.'s research and development capabilities in the cannabis sector.
Pipeline Development
Sangre AgroTech's key project is the Cannabis Genomic Study, which involves sequencing and annotating the genomes of multiple cannabis cultivars. The study's objectives include:
- Technical Objective 1: Using next-generation sequencing platforms and proprietary bioinformatics programs to sequence five cultivars of Cannabis and generate fully annotated genomic data.
- Technical Objective 2: Performing backcross and forward hybridization studies to produce new generations of stock, with the progeny being genetically fingerprinted and introduced to the market under patent protection.
These efforts are aimed at developing new, genetically enhanced strains of cannabis with desired characteristics for disease treatment and drug discovery.
Technological Platform and Innovation
Sangre AgroTech employs advanced genomic sequencing technologies, including the Illumina MiSeq and MinIon instruments, to extract, purify, sequence, and annotate cannabis DNA. The company utilizes proprietary bioinformatics systems to assemble and analyze genomic data, facilitating gene discovery and location. This approach enables the development of new, high-value cannabis strains through a gene-based breeding program, aiming to improve therapeutic properties and introduce integrity, stability, and quality to the market.
Leadership Team
The leadership team of Sangre AgroTech includes experienced professionals with expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry. Their combined experience and knowledge drive the company's research initiatives and strategic direction.
Competitor Profile
In the biopharmaceutical industry, Sangre AgroTech faces competition from several companies specializing in cannabis research and development. Key competitors include:
- Sangamo Therapeutics: A biotechnology company focused on genomic medicine, including gene therapy and gene editing.
- Myriad Genetics: Specializes in genetic testing and precision medicine.
- Lexicon Pharmaceuticals: Engages in the discovery and development of pharmaceutical products.
These companies have established market positions and continue to innovate in the field of genomic research and therapeutics.
Strategic Collaborations and Partnerships
Sangre AgroTech has engaged in discussions with organizations such as The Ministry of Health in Israel and the Therapeutic Goods Administration in Australia to conduct research studies. These collaborations aim to advance the company's research and development efforts in accordance with international laws and regulations.
Operational Insights
Sangre AgroTech's strategic focus on genomic research and the development of patented cannabis strains positions the company to capitalize on the growing demand for medical cannabis products. By leveraging advanced sequencing technologies and proprietary bioinformatics, the company aims to differentiate itself in the competitive landscape through innovation and intellectual property development.
Strategic Opportunities and Future Directions
Looking ahead, Sangre AgroTech plans to expand its research initiatives, develop new cannabis strains with enhanced therapeutic properties, and establish strategic partnerships to commercialize its products. The company's focus on intellectual property development and adherence to regulatory standards will be critical in achieving its long-term objectives in the medical cannabis industry.
Contact Information
For more information, visit Sangre AgroTech's website at www.sangreagrotech.com.
